Baraliakos X, et al. Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial. ACR 2018, abstract L13.
Verhoogd serum-CA72-4 voorspelt jichtaanvallen tijdens starten urinezuurverlagende therapie
nov 2022 | Jicht